A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects.
Latest Information Update: 01 Oct 2023
At a glance
- Drugs GSK 1292263 (Primary) ; Rosuvastatin; Simvastatin
- Indications Lipid metabolism disorders; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 30 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 30 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.